Abstract
Background: Recent data have described a survival advantage associated with the administration of hyperthermic intra-peritoneal chemotherapy(HIPEC) following complete cytoreductive surgery(CRS) in ovarian cancer(OC). It is unlikely that HIPEC administered as a single dose has sufficient direct cytotoxicity to account for the improved survival. We hypothesise that HIPEC improves outcome by aborting a surgery induced cytokine storm, thereby reducing the proliferative stimulus to residual tumour cells.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
